MYL4

Summary

MYL4 (myosin light chain 4, HGNC:7585) is a protein-coding gene on chromosome 17q21.32, encoding Myosin light chain 4 (P12829). Regulatory light chain of myosin.

Myosin is a hexameric ATPase cellular motor protein. It is composed of two myosin heavy chains, two nonphosphorylatable myosin alkali light chains, and two phosphorylatable myosin regulatory light chains. This gene encodes a myosin alkali light chain that is found in embryonic muscle and adult atria. Two alternatively spliced transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 4635 — RefSeq curated summary.

At a glance

• Gene–disease (curated): atrial fibrillation, familial, 18 (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 2
• Clinical variants (ClinVar): 297 total — 6 pathogenic, 10 likely-pathogenic
• Phenotypes (HPO): 18
• Druggable target: yes
• MANE Select transcript: NM_002476

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7585
Approved symbol	MYL4
Name	myosin light chain 4
Location	17q21.32
Locus type	gene with protein product
Status	Approved
Aliases	ALC1, AMLC, GT1, PRO1957
Ensembl gene	ENSG00000198336
Ensembl biotype	protein_coding
OMIM	160770
Entrez	4635

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 27 protein_coding, 3 nonsense_mediated_decay

ENST00000354968, ENST00000393450, ENST00000536623, ENST00000570671, ENST00000570772, ENST00000571981, ENST00000572303, ENST00000572316, ENST00000573747, ENST00000576874, ENST00000869091, ENST00000954741, ENST00000954742, ENST00000954743, ENST00000954744, ENST00000954745, ENST00000954746, ENST00000954747, ENST00000954748, ENST00000954749, ENST00000954750, ENST00000954751, ENST00000954752, ENST00000954753, ENST00000954754, ENST00000954755, ENST00000954756, ENST00000954757, ENST00000954758, ENST00000954759

RefSeq mRNA: 2 — MANE Select: NM_002476 NM_001002841, NM_002476

CCDS: CCDS11510

Canonical transcript exons

ENST00000393450 — 7 exons

Exon	Start	End
ENSE00001110506	47213799	47213826
ENSE00001515362	47223509	47223679
ENSE00001515363	47209348	47209557
ENSE00003499617	47219904	47220053
ENSE00003632633	47222380	47222457
ENSE00003644572	47221682	47221855
ENSE00003647293	47223014	47223057

Expression profiles

Bgee: expression breadth ubiquitous, 186 present calls, max score 99.94.

FANTOM5 (CAGE): breadth broad, TPM avg 51.3839 / max 11702.8514, expressed in 420 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161338	38.3511	342
161335	5.4304	325
161339	5.2919	186
161340	2.0531	154
161336	0.1247	68
161337	0.1020	60
161334	0.0305	13

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right atrium auricular region	UBERON:0006631	99.94	gold quality
cardiac atrium	UBERON:0002081	99.93	gold quality
cardiac muscle of right atrium	UBERON:0003379	99.92	gold quality
apex of heart	UBERON:0002098	99.28	gold quality
vena cava	UBERON:0004087	98.47	gold quality
myocardium	UBERON:0002349	97.22	gold quality
heart right ventricle	UBERON:0002080	96.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	96.22	gold quality
trabecular bone tissue	UBERON:0002483	96.04	gold quality
heart left ventricle	UBERON:0002084	95.50	gold quality
cardiac ventricle	UBERON:0002082	95.45	gold quality
heart	UBERON:0000948	93.80	gold quality
blood	UBERON:0000178	93.47	gold quality
bone marrow	UBERON:0002371	92.01	gold quality
tibialis anterior	UBERON:0001385	91.40	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	88.81	silver quality
triceps brachii	UBERON:0001509	88.55	silver quality
biceps brachii	UBERON:0001507	88.48	silver quality
gluteal muscle	UBERON:0002000	87.96	silver quality
left ventricle myocardium	UBERON:0006566	87.34	gold quality
bone marrow cell	CL:0002092	86.76	gold quality
right testis	UBERON:0004534	85.51	gold quality
diaphragm	UBERON:0001103	85.04	silver quality
monocyte	CL:0000576	84.47	gold quality
mononuclear cell	CL:0000842	84.28	gold quality
left testis	UBERON:0004533	83.70	gold quality
deltoid	UBERON:0001476	83.17	silver quality
leukocyte	CL:0000738	81.92	gold quality
testis	UBERON:0000473	81.43	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	80.78	silver quality

Single-cell (SCXA)

Detected in 19 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-GEOD-124472	yes	1601.07
E-MTAB-9388	yes	959.65
E-MTAB-7407	yes	907.90
E-MTAB-10042	yes	802.50
E-MTAB-8205	yes	581.18
E-GEOD-130473	yes	421.76
E-CURD-112	yes	370.39
E-HCAD-4	yes	150.61
E-MTAB-7316	yes	33.11
E-CURD-122	yes	18.41
E-MTAB-9221	yes	15.89
E-MTAB-8271	yes	9.69
E-MTAB-9067	yes	8.45
E-HCAD-9	yes	7.39
E-HCAD-10	yes	7.09

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MITF, MYF5, MYOD1, MYOG, NR2F2, SRF

miRNA regulators (miRDB)

5 targeting MYL4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-6784-3P	98.39	64.88	662
HSA-MIR-6862-3P	97.92	64.86	531
HSA-MIR-4726-5P	97.24	65.67	1299
HSA-MIR-3189-3P	96.80	66.34	896

Literature-anchored findings (GeneRIF, showing 9)

• NMR showed involvement of N-terminus and lysines 3 and 4 in interaction with actin. Mutations of these lysines (K3A,K4R,K4A,K4D) resulted in altered actin binding and actin activated MgATPase. Mutation of Ala-1 to val had no effect on binding or kinetics. (PMID:10373429)
• results demonstrate that the expression of hALC-1 could have a beneficial effect on the overloaded hypertrophied heart (PMID:16106982)
• A recessive frameshift mutation in MYL4 causes early-onset atrial fibrillation. (PMID:25807286)
• a novel, heterozygous p.Glu11Lys mutation in the atrial-specific myosin light chain gene MYL4, caused atrial fibrillation. (PMID:27066836)
• The authors describe in a population approach a loss of function mutation in the myosin gene MYL4 that, in the homozygous state, is completely penetrant for early-onset AF. The finding may provide novel mechanistic insight into the pathophysiology of this complex arrhythmia. (PMID:27742809)
• Metastable Atrial State Underlies the Primary Genetic Substrate for MYL4 Mutation-Associated Atrial Fibrillation. (PMID:31735076)
• Relationship between Serum miR-106 and MYL4 Levels and the Prevalence, Risk Stratification, and Prognosis of Atrial Fibrillation. (PMID:35874900)
• The (Ala-Pro) rich part of this protein acts as a “spacer arm” responsible for correct positioning of the N-terminal actin binding site. (PMID:9000508)
• The N-terminus of this protein is an actin binding site. (PMID:9738905)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	myl4	ENSDARG00000011519
danio_rerio	cmlc1	ENSDARG00000032976
danio_rerio	zgc:163073	ENSDARG00000099712
mus_musculus	Myl4	ENSMUSG00000061086
rattus_norvegicus	Myl4	ENSRNOG00000050675
drosophila_melanogaster	Mlc-c	FBGN0004687
caenorhabditis_elegans		WBGENE00010554
caenorhabditis_elegans		WBGENE00011734

Paralogs (4): MYL6 (ENSG00000092841), MYL3 (ENSG00000160808), MYL1 (ENSG00000168530), MYL6B (ENSG00000196465)

Protein

Protein identifiers

Myosin light chain 4 — P12829 (reviewed: P12829)

Alternative names: Myosin light chain 1, embryonic muscle/atrial isoform, Myosin light chain alkali GT-1 isoform

All UniProt accessions (7): A0A1C7CYY4, P12829, I3L1K6, I3L1R3, I3L3U1, I3L4B1, I3L532

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory light chain of myosin. Does not bind calcium.

Subunit / interactions. Myosin is a hexamer of 2 heavy chains and 4 light chains.

Disease relevance. Atrial fibrillation, familial, 18 (ATFB18) [MIM:617280] A familial form of atrial fibrillation, a common sustained cardiac rhythm disturbance. Atrial fibrillation is characterized by disorganized atrial electrical activity and ineffective atrial contraction promoting blood stasis in the atria and reduces ventricular filling. It can result in palpitations, syncope, thromboembolic stroke, and congestive heart failure. The disease is caused by variants affecting the gene represented in this entry.

RefSeq proteins (2): NP_001002841, NP_002467* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR050230	CALM/Myosin/TropC-like	Family

UniProt features (18 total): sequence conflict 7, compositionally biased region 3, sequence variant 2, domain 2, initiator methionine 1, chain 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P12829-F1	90.85	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-390522	Striated Muscle Contraction
R-HSA-397014	Muscle contraction

MSigDB gene sets: 245 (showing top): GOBP_CIRCULATORY_SYSTEM_PROCESS, XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, MODULE_329, GOLDRATH_ANTIGEN_RESPONSE, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_DN, GOBP_MUSCLE_CONTRACTION, MARTINEZ_RB1_TARGETS_DN, GOBP_REGULATION_OF_THE_FORCE_OF_HEART_CONTRACTION, TSENG_IRS1_TARGETS_DN, GOBP_REGULATION_OF_SYSTEM_PROCESS, GOMF_ACTIN_BINDING, GOBP_HEART_PROCESS, GOBP_MUSCLE_SYSTEM_PROCESS

GO Biological Process (3): regulation of the force of heart contraction (GO:0002026), muscle contraction (GO:0006936), cardiac muscle contraction (GO:0060048)

GO Molecular Function (4): actin monomer binding (GO:0003785), calcium ion binding (GO:0005509), myosin II heavy chain binding (GO:0032038), actin filament binding (GO:0051015)

GO Cellular Component (4): cytosol (GO:0005829), myosin II complex (GO:0016460), A band (GO:0031672), myosin complex (GO:0016459)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Muscle contraction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
actin binding	2
cellular anatomical structure	2
regulation of heart contraction	1
regulation of biological quality	1
muscle system process	1
striated muscle contraction	1
heart contraction	1
metal ion binding	1
myosin heavy chain binding	1
myosin II binding	1
protein-containing complex binding	1
cytoplasm	1
myosin complex	1
sarcomere	1
actin cytoskeleton	1
protein-containing complex	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

21 interactions, top by confidence:

A	B	Type	Score
S100A4	OIP5	psi-mi:“MI:0914”(association)	0.530
VCAM1	PSMD11	psi-mi:“MI:0914”(association)	0.530
PYROXD2	MYL4	psi-mi:“MI:0915”(physical association)	0.370
ALB	CNOT1	psi-mi:“MI:0914”(association)	0.350
rep	DDX3X	psi-mi:“MI:0914”(association)	0.350
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
FILIP1	DAPK3	psi-mi:“MI:0914”(association)	0.350
MYL4	MYL1	psi-mi:“MI:0914”(association)	0.350
MYL3	MYL4	psi-mi:“MI:0914”(association)	0.350
IQGAP3	CCDC85C	psi-mi:“MI:0914”(association)	0.350
MYL12B	MYL1	psi-mi:“MI:0914”(association)	0.350
TTC4	MYH7B	psi-mi:“MI:0914”(association)	0.350
VCAM1		psi-mi:“MI:0914”(association)	0.350
FN1	ESYT2	psi-mi:“MI:0914”(association)	0.350
GPKOW	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
LARP7	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
SBDS	RPSA2	psi-mi:“MI:2364”(proximity)	0.270
ZC3H11A	ESYT2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (25): MYL4 (Affinity Capture-MS), MYL4 (Affinity Capture-MS), MYL4 (Affinity Capture-MS), MYL4 (Affinity Capture-MS), MYL1 (Affinity Capture-MS), MYO18A (Affinity Capture-MS), CAMKK2 (Affinity Capture-MS), MYL4 (Affinity Capture-MS), MYL4 (Affinity Capture-MS), OSBPL11 (Affinity Capture-MS), IQGAP1 (Affinity Capture-MS), OSBPL9 (Affinity Capture-MS), UBE3B (Affinity Capture-MS), CDC42 (Affinity Capture-MS), IQGAP3 (Affinity Capture-MS)

ESM2 similar proteins: A0A125YHX7, A0JNJ5, F1RRT2, J7HCX7, O15182, O35648, P02600, P02602, P02604, P02605, P02606, P05434, P05976, P05977, P06742, P08590, P09540, P09541, P09542, P12829, P14649, P16409, P17209, P41044, P41208, P41209, P53014, P53441, P54213, P54357, P82159, P82160, P85100, Q06827, Q09196, Q12798, Q24621, Q24654, Q24756, Q27177

Diamond homologs: A0JNJ5, A2Y609, A3E3H0, A3E4D8, A3E4F9, A4UHC0, A8CEP3, A8I1Q0, F1RRT2, J7HCX7, O14008, O60041, O82018, O94739, P02597, P02598, P02600, P02602, P02604, P02605, P02606, P02607, P04353, P04464, P05419, P05976, P05977, P06742, P06787, P07290, P07291, P07462, P07463, P08053, P08590, P09540, P09541, P09542, P0DH95, P0DH96

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
“MYOD1/SWI/SNF complex”	“up-regulates quantity by expression”	MYL4	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

297 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	10
Uncertain significance	156
Likely benign	98
Benign	21

Top pathogenic / likely-pathogenic (16)

Variant ID	HGVS	Classification
2053340	NM_002476.2(MYL4):c.532C>T (p.Gln178Ter)	Pathogenic
2165639	NM_002476.2(MYL4):c.361C>T (p.Gln121Ter)	Pathogenic
224067	NM_002476.2(MYL4):c.31G>A (p.Glu11Lys)	Pathogenic
3243111	NC_000017.10:g.(?45291145)(45291212_?)del	Pathogenic
3656250	NM_002476.2(MYL4):c.187_190del (p.Phe63fs)	Pathogenic
3725515	NM_002476.2(MYL4):c.455del (p.Gly152fs)	Pathogenic
1474944	NM_002476.2(MYL4):c.487+1G>A	Likely pathogenic
2052621	NM_002476.2(MYL4):c.314-1G>C	Likely pathogenic
2090713	NM_002476.2(MYL4):c.313+1G>T	Likely pathogenic
2147045	NM_002476.2(MYL4):c.135+1G>A	Likely pathogenic
3020997	NM_002476.2(MYL4):c.164-1G>C	Likely pathogenic
3366361	NM_002476.2(MYL4):c.234C>A (p.Cys78Ter)	Likely pathogenic
3630172	NM_002476.2(MYL4):c.163+1G>A	Likely pathogenic
4728001	NM_002476.2(MYL4):c.136-2A>C	Likely pathogenic
476205	NM_002476.2(MYL4):c.487+1G>C	Likely pathogenic
648701	NM_002476.2(MYL4):c.488-1G>A	Likely pathogenic

SpliceAI

1349 predictions. Top by Δscore:

Variant	Effect	Δscore
17:47209558:G:GG	donor_gain	1.0000
17:47219902:A:AG	acceptor_gain	1.0000
17:47219903:G:GG	acceptor_gain	1.0000
17:47219903:GA:G	acceptor_gain	1.0000
17:47219933:C:A	acceptor_gain	1.0000
17:47221665:A:AG	acceptor_gain	1.0000
17:47221665:ACCCT:A	acceptor_gain	1.0000
17:47221666:C:G	acceptor_gain	1.0000
17:47221669:T:TA	acceptor_gain	1.0000
17:47221673:T:A	acceptor_gain	1.0000
17:47221673:T:TA	acceptor_loss	1.0000
17:47221677:T:TA	acceptor_gain	1.0000
17:47221677:TGAA:T	acceptor_loss	1.0000
17:47221680:A:AG	acceptor_gain	1.0000
17:47221680:AGAG:A	acceptor_loss	1.0000
17:47221681:G:GG	acceptor_gain	1.0000
17:47221681:GA:G	acceptor_gain	1.0000
17:47221681:GAGA:G	acceptor_gain	1.0000
17:47221681:GAGAT:G	acceptor_gain	1.0000
17:47221801:G:GT	donor_gain	1.0000
17:47221802:A:T	donor_gain	1.0000
17:47221854:GG:G	donor_gain	1.0000
17:47221855:GG:G	donor_gain	1.0000
17:47221856:G:GC	donor_loss	1.0000
17:47221857:T:A	donor_loss	1.0000
17:47222378:A:AG	acceptor_gain	1.0000
17:47222379:G:GG	acceptor_gain	1.0000
17:47222455:AAG:A	donor_loss	1.0000
17:47222457:GGTAT:G	donor_gain	1.0000
17:47222458:G:T	donor_loss	1.0000

AlphaMissense

1293 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:47219927:T:C	F63L	1.000
17:47219929:T:A	F63L	1.000
17:47219929:T:G	F63L	1.000
17:47221784:T:C	L139P	1.000
17:47221792:T:C	F142L	1.000
17:47221794:T:A	F142L	1.000
17:47221794:T:G	F142L	1.000
17:47221817:T:A	V150D	1.000
17:47221832:T:C	L155P	1.000
17:47222380:G:A	G163E	1.000
17:47219918:T:C	F60L	0.999
17:47219920:T:A	F60L	0.999
17:47219920:T:G	F60L	0.999
17:47219972:T:C	C78R	0.999
17:47219976:G:A	G79E	0.999
17:47219988:G:C	R83P	0.999
17:47221727:T:C	L120P	0.999
17:47221780:G:C	G138R	0.999
17:47221781:G:A	G138D	0.999
17:47221787:G:C	R140P	0.999
17:47221792:T:A	F142I	0.999
17:47221792:T:G	F142V	0.999
17:47221793:T:C	F142S	0.999
17:47221793:T:G	F142C	0.999
17:47221795:G:C	D143H	0.999
17:47221796:A:C	D143A	0.999
17:47221796:A:T	D143V	0.999
17:47221800:G:C	K144N	0.999
17:47221800:G:T	K144N	0.999
17:47221811:G:T	G148V	0.999

dbSNP variants (sampled 300 via entrez): RS1000046914 (17:47197130 G>A,T), RS1000151843 (17:47210063 T>G), RS1000171905 (17:47220462 A>C,G), RS1000280689 (17:47198766 G>A), RS1000356004 (17:47214730 A>C,G), RS1000561625 (17:47221552 A>G,T), RS1000580404 (17:47205703 C>G), RS1000677634 (17:47211744 G>A), RS1000690398 (17:47225855 C>A,T), RS1000742671 (17:47216108 T>C), RS1000769098 (17:47205309 T>A), RS1000848796 (17:47202806 A>G), RS1001057799 (17:47218194 A>G), RS1001078680 (17:47209823 A>G), RS1001084067 (17:47224227 C>T)

Disease associations

OMIM: gene MIM:160770 | disease phenotypes: MIM:617280, MIM:608583

GenCC curated gene-disease

Disease	Classification	Inheritance
atrial fibrillation, familial, 18	Strong	Autosomal dominant
familial atrial fibrillation	Supportive	Autosomal dominant

Mondo (2): atrial fibrillation, familial, 18 (MONDO:0015001), familial atrial fibrillation (MONDO:0018054)

Orphanet (1): Hereditary atrial fibrillation (Orphanet:334)

HPO phenotypes

18 total (18 of 18 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001279	Syncope
HP:0001658	Myocardial infarction
HP:0001662	Bradycardia
HP:0001709	Third degree atrioventricular block
HP:0001727	Thromboembolic stroke
HP:0001907	Thromboembolism
HP:0001962	Palpitations
HP:0002094	Dyspnea
HP:0002321	Vertigo
HP:0003546	Exercise intolerance
HP:0004754	Permanent atrial fibrillation
HP:0004757	Paroxysmal atrial fibrillation
HP:0005110	Atrial fibrillation
HP:0011462	Young adult onset
HP:0011705	First degree atrioventricular block
HP:0012378	Fatigue
HP:0100749	Chest pain

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002380_5	Erythema nodosum in inflammatory bowel disease	8.000000e-06
GCST005951_16	Body mass index	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3831286 (PROTEIN COMPLEX), CHEMBL6066959 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.44	Kd	36.39	nM	CHEMBL5653589
6.93	ED50	118.4	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148808: Binding affinity to human MYL4 incubated for 45 mins by Kinobead based pull down assay	kd	0.0364	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	3
bisphenol A	increases expression	2
Doxorubicin	affects expression	2
ascorbate-2-phosphate	affects binding, affects cotreatment, increases expression	1
sodium arsenite	increases expression	1
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	affects cotreatment, decreases expression	1
diethyl malate	increases expression	1
azoxystrobin	decreases expression	1
CGP 52608	affects binding, increases reaction	1
deguelin	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
Chir 99021	affects binding, increases expression, affects cotreatment, decreases expression	1
clothianidin	decreases expression	1
thifluzamide	decreases expression	1
abrine	increases expression	1
pyrachlostrobin	decreases expression	1
XAV939	affects binding, affects cotreatment, increases expression	1
incobotulinumtoxinA	decreases expression	1
picoxystrobin	decreases expression	1
3-(4-pyridyl)-1H-indole	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	increases expression	1
Acetaminophen	decreases expression	1
Amiodarone	increases expression	1
Arsenic	affects methylation	1
Ascorbic Acid	affects binding, affects cotreatment, increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Capsaicin	decreases expression	1
Carbamazepine	affects expression	1
Cytarabine	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651850	Binding	Binding affinity to human MYL4 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

2 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04075994	Not specified	COMPLETED	Atrial Fibrillation Health Literacy and Information Technology Trial
NCT04076020	Not specified	COMPLETED	Atrial Fibrillation Health Literacy and Information Technology Trial in Rural Pennsylvania Counties